Remegen Biopharmaceutical (Yantai) Co., Ltd. voluntarily disclosed an announcement about Tai.tasirumab achieving the primary study endpoint in Phase III clinical studies of myasthenia gravis.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.